Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear‐cell renal cell carcinoma patients treated with sunitinib

No abstract is available for this paper.

• Publication year

  2016

• Venue

  BJU International

• Publication date

  2016-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bju.13585PMID 27417418
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of polymorphisms in angiogenesis-related genes as predictive and prognostic markers for sunitinib-treated metastatic renal cell carcinoma patients

  2016cited by this paper
• Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.

  2015cited by this paper
• Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting

  2015cited by this paper
• Single-Nucleotide Polymorphisms in the Vascular Endothelial Growth Factor Pathway and Outcomes of Patients Treated with First-Line Cytotoxic Chemotherapy Combined with Bevacizumab for Advanced Colorectal Cancer

  2014cited by this paper
• VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis

  2014cited by this paper
• Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.

  2014cited by this paper
• Markers of response for the antiangiogenic agent bevacizumab.

  2013cited by this paper
• Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab

  2013cited by this paper
• Analyses of Potential Predictive Markers and Survival Data for a Response to Sunitinib in Patients with Metastatic Renal Cell Carcinoma

  2013cited by this paper
• The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer

  2012cited by this paper
• VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

  2012cited by this paper
• Optimized filtering reduces the error rate in detecting genomic variants by short-read sequencing

  2011cited by this paper
• Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

  2011cited by this paper
• Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

  2011cited by this paper
• Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays

  2009cited by this paper
• Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

  2009cited by this paper
• Resistance to targeted therapy in renal-cell carcinoma.

  2009cited by this paper
• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

  2009cited by this paper
• Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

  2007cited by this paper

• Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.

  2026cites this paper
• VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol

  2025cites this paper
• The Association of Soluble VEGFR-1 Serum Level and Genetic (rs7993418) Polymorphism with In Vitro Fertilization and Embryo Transfer Outcome in the Population of Northern Iran

  2023cites this paper
• Research Progress on Circulating Tumor DNA in Renal Cell Carcinoma

  2023cites this paper
• Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial

  2022cites this paper
• The Association of Biochemical and Genetic Biomarkers in VEGF Pathway with Depression

  2022cites this paper
• Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients

  2022cites this paper
• Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies

  2022cites this paper
• A multicenter phase II study of pazopanib in patients with unresectable dermatofibrosarcoma protuberans.

  2020cites this paper
• Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib

  2020cites this paper
• Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy

  2019cites this paper
• Fibroblast Growth Factor Receptor‐2 Polymorphism rs2981582 is Correlated With Progression‐free Survival and Overall Survival in Patients With Metastatic Clear‐cell Renal Cell Carcinoma Treated With Sunitinib

  2019cites this paper
• Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma

  2019cites this paper
• Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.

  2019cites this paper
• Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma.

  2019cites this paper
• Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear‐Cell Renal‐Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors

  2018cites this paper
• Optimization of sunitinib treatment in metastatic renal cell carcinoma

  2018cites this paper
• Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis

  2018cites this paper
• Bioinformatic identification of key genes and analysis of prognostic values in clear cell renal cell carcinoma

  2018cites this paper
• Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma

  2018cites this paper
• Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma

  2018cites this paper
• Immunological Approaches Towards Cancer and Inflammation: A Cross Talk

  2018cites this paper
• Biomarker classification, validation, and what to look for in 2017 and beyond

  2017cites this paper
• FLT-1 gene polymorphisms and protein expression profile in rheumatoid arthritis

  2017cites this paper
• Effects of VEGF and VEGFR polymorphisms on the outcome of patients with metastatic renal cell carcinoma treated with sunitinib: a systematic review and meta-analysis

  2017cites this paper
• Single nucleotide polymorphisms of the vascular endothelial growth factor receptor – a promising biomarker in metastatic renal cell carcinoma

  2016cites this paper
• Predicting angiogenic receptor trafficking and signaling via computational systems biology

  2016cites this paper
• Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

  2016influential citation